Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

Share this content:
Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.
Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.

Title: Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma1

Description: For this randomized phase 3 study (ClinicalTrials.gov Identifier: NCT02546102), researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma. ICT-107 may be effective for activating cytotoxic T cells to target tumor cells.

There are 2 trial arms: in arm 1, patients will receive ICT-107 with temozolomide; in arm 2, patients will receive temozolomide with placebo.

The primary outcome is overall survival. Secondary outcomes include progression-free survival and frequency/variety of adverse events.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/study/NCT02546102.

Status: This study is open and recruiting patients as of February 24, 2017.

This study is sponsored by ImmunoCellular Therapeutics, Ltd in collaboration with Novella Clinical. Phase 1 trial data about the efficacy of ICT-107 can be found in an article published in Cancer Immunology, Immunotherapy.2

Reference

  1. Clinicaltrials.gov. A phase 3 randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy. NCT02546102. https://clinicaltrials.gov/ct2/show/study/NCT02546102. Accessed February 24, 2017.
  2. Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1):125-35. doi: 10.1007/s00262-012-1319-0

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters